Sidewinder Therapeutics Inks $137M Series B Financing
2026-04-08
Tweet
SAN DIEGO, CA, Sidewinder Therapeutics, a biopharmaceutical company, announced the closing of an oversubscribed $137 million Series B financing.
Sidewinder Therapeutics, a biopharmaceutical company pioneering the development of next-generation bispecific ADCs (antibody-drug conjugates) for the treatment of cancer, announced the closing of an oversubscribed $137 million Series B financing.
The round was co-led by Frazier Life Sciences and Novartis Venture Fund, with participation from the sole Series A investor OrbiMed as well as new investors including Life Sciences at Goldman Sachs Alternatives, DCVC Bio, Samsara BioCapital, Longwood Fund, Astellas Venture Management and Alexandria Venture Investments.
The round was co-led by Frazier Life Sciences and Novartis Venture Fund, with participation from the sole Series A investor OrbiMed as well as new investors including Life Sciences at Goldman Sachs Alternatives, DCVC Bio, Samsara BioCapital, Longwood Fund, Astellas Venture Management and Alexandria Venture Investments.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors
